Actinogen Medical Executes 60,001 Options at AUD $0.0375, Boosting Share Capital

Overview of Actinogen Medical and Its Capital Structure

Actinogen Medical Limited (ACN 086778476) is an ASX-listed pharmaceutical development company focused on innovative treatments. Its capital structure includes multiple classes of securities such as ordinary shares and various option series with differing expiration dates and exercise prices. This layered structure supports equity financing and incentivizes employees and investors, aligning stakeholder interests with the company’s long-term goals.

The ordinary shares form the core equity ownership, while the outstanding options represent potential future dilution as holders convert them into shares. Understanding the mix and expiry timelines of these convertible securities is essential for investors evaluating future share count and equity structure. The recent ACWAO option exercise reflects active conversion within Actinogen Medical’s capital base.

Details of the 60,001 Newly Quoted Ordinary Shares on ASX

On 21 July 2026, Actinogen Medical completed the listing of 60,001 ordinary fully paid shares on the ASX. These shares resulted from exercising 60,001 ACWAO options, each with a strike price of AUD $0.0375. The exercise and quotation occurred on the same day, confirming a swift transaction process. The new shares rank equally with all existing ordinary shares from the date of issue.

The AUD $0.0375 exercise price was set at the time of the ACWAO options issuance and remains fixed through expiry. This conversion increases the company’s equity capital and reduces the outstanding unquoted option pool. As of the announcement, 75,304,717 ACWAO options remain unexercised, expiring on 11 September 2026, indicating a limited timeframe for further conversions.

Expanded Ordinary Share Capital Post-Conversion

Following the addition of the 60,001 shares, Actinogen Medical’s total issued ordinary fully paid shares now amount to 3,717,151,614. This increase is modest relative to the total share count but contributes to the company’s equity base. The shares were issued and quoted on 21 July 2026, becoming immediately tradable on the ASX.

Ordinary shares carry full voting and dividend rights. While option exercises dilute existing shareholders, the impact from this conversion is minimal given the small volume. Investors should monitor the company’s capital management and future option exercises to assess potential dilution effects.

Outstanding Unquoted Options and Approaching Expiration Dates

As of 21 July 2026, Actinogen Medical holds two major unquoted option series: 75,304,717 ACWAO options expiring 11 September 2026, and 71,873,727 ACWAP options expiring 15 September 2026. Both series have an exercise price of AUD $0.0375 and face imminent expiration, requiring option holders to act before these deadlines or forfeit conversion rights.

The expiration timeline is critical for capital planning. Option holders must exercise before expiry to convert options into shares; otherwise, the options lapse worthless. The outstanding options represent potential future equity issuance, but some may expire unexercised, mitigating dilution. Investors should track these dates and any significant exercise announcements as they may materially affect ownership and earnings per share.

Additional Quoted Option Series on ASX

In addition to unquoted options, Actinogen Medical has two large quoted option series: 277,249,773 ACWOC options expiring 30 September 2027, and 175,441,171 ACWOD options expiring 31 May 2027. These quoted options represent a substantial portion of convertible securities with longer expiry horizons extending into 2027.

Collectively, the ACWOC and ACWOD series total approximately 452 million options actively traded on the ASX. These extended expiration dates provide holders with more time to decide on exercising options compared to the near-term ACWAO and ACWAP expiries. The exercise prices for these quoted options were not disclosed in this update but constitute a significant factor in the company’s potential future equity dilution.

Option Exercise Currency and Pricing Details

All ACWAO option exercises, including the recent 60,001 share conversion, are conducted in Australian dollars (AUD). The exercise price is fixed at AUD $0.0375 per share across the ACWAO series, establishing a uniform conversion price for option holders. This price was set at issuance and remains unchanged through expiration regardless of market fluctuations.

This fixed strike price allows option holders to benefit if ACW’s share price exceeds AUD $0.0375 by acquiring shares below market value. Conversely, if the share price is below the exercise price, holders typically let options expire worthless. The AUD denomination aligns with the company’s Australian listing and investor base, minimizing foreign exchange risk and simplifying settlement.

Capital Structure and Investor Considerations

Actinogen Medical’s multi-class security framework reflects a strategic capital management approach, balancing ordinary shares with multiple option series of varying expiry dates. This structure enables controlled dilution timing and provides flexibility for employees, investors, and partners holding convertible securities.

For existing shareholders, ongoing option exercises present dilution risks that should be factored into valuation and earnings per share forecasts. The company’s total issued capital now includes 3,717,151,614 ordinary shares, 277,249,773 ACWOC options, 175,441,171 ACWOD options, 71,873,727 ACWAP options, and 75,304,717 ACWAO options. Future conversions will impact weighted average share count and per-share financial metrics reported in financial disclosures.

Exercise Deadlines for Option Holders Before September 2026 Expiry

Option holders of the ACWAO and ACWAP series face critical exercise deadlines in mid-September 2026. The ACWAO options (75,304,717) expire on 11 September 2026, and the ACWAP options (71,873,727) expire on 15 September 2026. Holders who have not exercised by these dates will lose the right to convert options into shares.

Holders must evaluate the AUD $0.0375 exercise price against the current ACW share price to decide on exercising. If the market price is substantially above AUD $0.0375, exercising is financially advantageous. If below, holders generally allow options to lapse. Considerations such as transaction costs, tax impacts, and investment goals also influence exercise decisions. The company did not disclose the current share price in this announcement, requiring holders to assess market conditions independently.

Regulatory Compliance and Quotation Process for New Shares

The quotation of the 60,001 newly issued ordinary shares complied with ASX Listing Rules, specifically Appendix 2A, which governs securities issued via option exercise or convertible security conversion. Actinogen Medical’s application for quotation was submitted on 21 July 2026, confirming the shares meet all ASX listing requirements and rank equally with existing ordinary shares.

This regulatory process ensures transparency and market integrity by mandating prompt disclosure of capital structure changes. The Appendix 2A filing provides investors with detailed information on the securities issued, conversion terms, and updated capital structure. Such disclosures enable investors to monitor dilution and make informed investment decisions. The quotation application is a standard corporate governance practice within the Australian securities market for companies with outstanding convertible securities.